A citation-based method for searching scientific literature

Plinio C Casarotto, Mykhailo Girych, Senem M Fred, Vera Kovaleva, Rafael Moliner, Giray Enkavi, Caroline Biojone, Cecilia Cannarozzo, Madhusmita Pryiadrashini Sahu, Katja Kaurinkoski, Cecilia A Brunello, Anna Steinzeig, Frederike Winkel, Sudarshan Patil, Stefan Vestring, Tsvetan Serchov, Cassiano R A F Diniz, Liina Laukkanen, Iseline Cardon, Hanna Antila, Tomasz Rog, Timo Petteri Piepponen, Clive R Bramham, Claus Normann, Sari E Lauri, Mart Saarma, Ilpo Vattulainen, Eero Castrén. Cell 2021
Times Cited: 142







List of co-cited articles
1008 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
28

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
860
27

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
26

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
24

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
22

Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
R N Moda-Sava, M H Murdock, P K Parekh, R N Fetcho, B S Huang, T N Huynh, J Witztum, D C Shaver, D L Rosenthal, E J Alway,[...]. Science 2019
243
16

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
408
14

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
839
14


Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
Eric W Lumsden, Timothy A Troppoli, Scott J Myers, Panos Zanos, Yasco Aracava, Jan Kehr, Jacqueline Lovett, Sukhan Kim, Fu-Hua Wang, Staffan Schmidt,[...]. Proc Natl Acad Sci U S A 2019
78
15

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Panos Zanos, Jaclyn N Highland, Brent W Stewart, Polymnia Georgiou, Carleigh E Jenne, Jacqueline Lovett, Patrick J Morris, Craig J Thomas, Ruin Moaddel, Carlos A Zarate,[...]. Proc Natl Acad Sci U S A 2019
73
16

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.
Kenichi Fukumoto, Manoela V Fogaça, Rong-Jian Liu, Catharine Duman, Taro Kato, Xiao-Yuan Li, Ronald S Duman. Proc Natl Acad Sci U S A 2019
94
12

Neurotrophin regulation of neural circuit development and function.
Hyungju Park, Mu-ming Poo. Nat Rev Neurosci 2013
12

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
742
12

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
11

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Jaclyn N Highland, Panos Zanos, Lace M Riggs, Polymnia Georgiou, Sarah M Clark, Patrick J Morris, Ruin Moaddel, Craig J Thomas, Carlos A Zarate, Edna F R Pereira,[...]. Pharmacol Rev 2021
31
35

Ketamine: A Paradigm Shift for Depression Research and Treatment.
John H Krystal, Chadi G Abdallah, Gerard Sanacora, Dennis S Charney, Ronald S Duman. Neuron 2019
154
11

Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
361
10

Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
Argel Aguilar-Valles, Danilo De Gregorio, Edna Matta-Camacho, Mohammad J Eslamizade, Abdessattar Khlaifia, Agnieszka Skaleka, Martha Lopez-Canul, Angelica Torres-Berrio, Sara Bermudez, Gareth M Rurak,[...]. Nature 2021
34
29

Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.
Thu Ha Pham, Céline Defaix, Xiaoming Xu, Shi-Xian Deng, Nicolas Fabresse, Jean-Claude Alvarez, Donald W Landry, Rebecca A Brachman, Christine A Denny, Alain M Gardier. Biol Psychiatry 2018
86
11

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
Dylan Chou, Hsien-Yu Peng, Tzer-Bin Lin, Cheng-Yuan Lai, Ming-Chun Hsieh, Yang-Cheng Wen, An-Sheng Lee, Hsueh-Hsiao Wang, Po-Sheng Yang, Gin-Den Chen,[...]. Neuropharmacology 2018
51
19

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
Cristan A Farmer, Jessica R Gilbert, Ruin Moaddel, Jomy George, Lilian Adeojo, Jacqueline Lovett, Allison C Nugent, Bashkim Kadriu, Peixiong Yuan, Todd D Gould,[...]. Neuropsychopharmacology 2020
32
31


Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback,[...]. Eur Arch Psychiatry Clin Neurosci 2021
100
10

BDNF - a key transducer of antidepressant effects.
Carl Björkholm, Lisa M Monteggia. Neuropharmacology 2016
485
10

A molecular and cellular theory of depression.
R S Duman, G R Heninger, E J Nestler. Arch Gen Psychiatry 1997
10

A neurotrophic model for stress-related mood disorders.
Ronald S Duman, Lisa M Monteggia. Biol Psychiatry 2006
10

GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.
Danielle M Gerhard, Santosh Pothula, Rong-Jian Liu, Min Wu, Xiao-Yuan Li, Matthew J Girgenti, Seth R Taylor, Catharine H Duman, Eric Delpire, Marina Picciotto,[...]. J Clin Invest 2020
108
10

Fear erasure in mice requires synergy between antidepressant drugs and extinction training.
Nina N Karpova, Anouchka Pickenhagen, Jesse Lindholm, Ettore Tiraboschi, Natalia Kulesskaya, Arna Agústsdóttir, Hanna Antila, Dina Popova, Yumiko Akamine, Amine Bahi,[...]. Science 2011
262
9


The molecular neurobiology of depression.
Vaishnav Krishnan, Eric J Nestler. Nature 2008
9


Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-Ichi Yamaguchi, Kenji Hashimoto, Shigeyuki Chaki. J Pharmacol Exp Ther 2017
139
8

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
197
8

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Carlos A Zarate, Nancy Brutsche, Gonzalo Laje, David A Luckenbaugh, Swarajya L Vattem Venkata, Anuradha Ramamoorthy, Ruin Moaddel, Irving W Wainer. Biol Psychiatry 2012
187
8

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
332
8

NMDAR-independent, cAMP-dependent antidepressant actions of ketamine.
Nathan H Wray, Jeffrey M Schappi, Harinder Singh, Nicolas B Senese, Mark M Rasenick. Mol Psychiatry 2019
64
12

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
Lace M Riggs, Yasco Aracava, Panos Zanos, Jonathan Fischell, Edson X Albuquerque, Edna F R Pereira, Scott M Thompson, Todd D Gould. Neuropsychopharmacology 2020
26
30

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
Jun-Ichi Yamaguchi, Hidetoh Toki, Youge Qu, Chun Yang, Hiroyuki Koike, Kenji Hashimoto, Akiko Mizuno-Yasuhira, Shigeyuki Chaki. Neuropsychopharmacology 2018
60
13

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.
Patrick J Morris, Ruin Moaddel, Panos Zanos, Curtis E Moore, Todd D Gould, Carlos A Zarate, Craig J Thomas. Org Lett 2017
41
19

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R Williams, Boris D Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David M Lyons, Carolyn I Rodriguez,[...]. Am J Psychiatry 2018
221
8

Acute suppression of spontaneous neurotransmission drives synaptic potentiation.
Elena Nosyreva, Kristen Szabla, Anita E Autry, Alexey G Ryazanov, Lisa M Monteggia, Ege T Kavalali. J Neurosci 2013
175
8

Decreased expression of synapse-related genes and loss of synapses in major depressive disorder.
Hyo Jung Kang, Bhavya Voleti, Tibor Hajszan, Grazyna Rajkowska, Craig A Stockmeier, Pawel Licznerski, Ashley Lepack, Mahesh S Majik, Lak Shin Jeong, Mounira Banasr,[...]. Nat Med 2012
458
8

BDNF release is required for the behavioral actions of ketamine.
Ashley E Lepack, Manabu Fuchikami, Jason M Dwyer, Mounira Banasr, Ronald S Duman. Int J Neuropsychopharmacol 2014
230
8

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Panos Zanos, Jaclyn N Highland, Xin Liu, Timothy A Troppoli, Polymnia Georgiou, Jacqueline Lovett, Patrick J Morris, Brent W Stewart, Craig J Thomas, Scott M Thompson,[...]. Br J Pharmacol 2019
42
16


Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.
Ruin Moaddel, Galia Abdrakhmanova, Joanna Kozak, Krzysztof Jozwiak, Lawrence Toll, Lucita Jimenez, Avraham Rosenberg, Thao Tran, Yingxian Xiao, Carlos A Zarate,[...]. Eur J Pharmacol 2013
115
7

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.
Jaclyn N Highland, Patrick J Morris, Panos Zanos, Jacqueline Lovett, Soumita Ghosh, Amy Q Wang, Carlos A Zarate, Craig J Thomas, Ruin Moaddel, Todd D Gould. J Psychopharmacol 2019
21
33

Effects of a ketamine metabolite on synaptic NMDAR function.
Kanzo Suzuki, Elena Nosyreva, Kevin W Hunt, Ege T Kavalali, Lisa M Monteggia. Nature 2017
109
7

Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Chun Yang, Qian Ren, Youge Qu, Ji-Chun Zhang, Min Ma, Chao Dong, Kenji Hashimoto. Biol Psychiatry 2018
133
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.